Venus Concept Inc.

VERO

US92332W2044

Advanced Medical Equipment & Technology

Delayed Nasdaq Other stock markets 11:48:15 2024-05-21 am EDT			5-day change	1st Jan Change
0.63 ^USD	+0.03%		-2.54%	-46.61%

May. 15	Transcript : Venus Concept Inc., Q1 2024 Earnings Call, May 15, 2024
May. 15	Venus Concept Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Venus Concept Inc. Announces Separation of Boris Vaynberg as Chief Technology Officer

July 10, 2020 at 04:12 pm EDT

Effective July 9, 2020, Boris Vaynberg, Venus Concept Inc.’s (the “Company”) Chief Technology Officer separated from service with the Company.

Latest news about Venus Concept Inc.

Transcript : Venus Concept Inc., Q1 2024 Earnings Call, May 15, 2024	May. 15
Venus Concept Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Earnings Flash (VERO) VENUS CONCEPT Posts Q1 Revenue $17.5M, vs. Street Est of $16.7M	May. 15	MT
Venus Concept Inc. Provides Earnings Guidance for the Three Months Ending June 30, 2024	May. 15	CI
Madryn Asset Management Delivers a Nonbinding Transaction Proposal to Venus Concept	May. 07	CI
Venus Concept Inc. Announces Israeli Regulatory Approval for Venus Bliss MAX	Apr. 08	CI
Transcript : Venus Concept Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
Venus Concept Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Venus Concept Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 01	CI
Earnings Flash (VERO) VENUS CONCEPT Posts Q4 Revenue $18.1M	Apr. 01	MT
Venus Concept Inc. Provides Earning Guidance for the Three Months Ended March 31, 2024	Apr. 01	CI
Venus Concept Continues Listing on Nasdaq, Gets May Deadline to Meet Equity Requirement	Mar. 25	MT
Certain Options of Venus Concept Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Venus Concept Inc. announced that it has received CAD 1.095782 million in funding	Mar. 06	CI
Venus Concept Inc. announced that it expects to receive CAD 1.095782 million in funding	Feb. 26	CI
Madryn Asset Provides Information to the Shareholders	Feb. 22	CI
Venus Concept Announces Review of Strategic Alternatives	Jan. 24	CI
Venus Concept Inc. announced that it has received CAD 2 million in funding from Essex Woodlands Management, Inc. and another investor	Jan. 17	CI
Venus Concept Inc. Announces New International Distributors in the United Kingdom and India to Continue Global Growth	Dec. 18	CI
Transcript : Venus Concept Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Venus Concept Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (VERO) VENUS CONCEPT Reports Q3 Revenue $17.6M, vs. Street Est of $17.5M	Nov. 14	MT
Earnings Flash (VERO) VENUS CONCEPT Posts Q3 Revenue $17.6M, vs. Street Est of $17.5M	Nov. 14	MT
Venus Concept Inc. Provides Earnings Guidance for the Twelve Months Ending December 31, 2023	Nov. 14	CI
Venus Concept Inc. Launches Venus Versa Pro, its New Multi-Application Platform for Face and Body Treatments	Nov. 01	CI

Venus Concept Inc. is a global medical aesthetic technology company. The Company has a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches in over 60 countries and 14 direct markets. The Company's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. The Company's systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry's traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company's hair loss treatment solutions include the ARTAS Solution and the NeoGraft Solution.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Venus Concept Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.6298

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
VENUS CONCEPT INC.	-46.61%	4M
THERMO FISHER SCIENTIFIC	+11.22%	227B
DANAHER CORPORATION	+15.27%	198B
INTUITIVE SURGICAL, INC.	+18.07%	142B
BOSTON SCIENTIFIC CORPORATION	+31.31%	111B
SIEMENS HEALTHINEERS AG	+1.56%	64.16B
EDWARDS LIFESCIENCES CORPORATION	+18.27%	54.1B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+5.12%	51.41B
AGILENT TECHNOLOGIES, INC.	+10.61%	45.32B
GE HEALTHCARE TECHNOLOGIES INC.	+5.12%	37.32B

Other Advanced Medical Equipment & Technology